Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.
NCT06507878 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 459
Last updated 2026-03-12
Summary
The goal of this clinical research study is to learn about the barriers in the real world to accessing treatments for ATC. And to learn about how patients with ATC tolerate and respond to the commercially available medications for treatment of this disease, outside of a clinical study.
Conditions
Sponsors & Collaborators
-
M.D. Anderson Cancer Center
lead OTHER
Principal Investigators
-
Priyanka C Iyer, MBBS · M.D. Anderson Cancer Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-05
- Primary Completion
- 2032-07-01
- Completion
- 2034-07-01
Countries
- United States
Study Locations
More Related Trials
-
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
NCT00390325 ·Status: COMPLETED ·Phase: PHASE2
-
Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
NCT00100828 ·Status: TERMINATED ·Phase: PHASE2
-
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
NCT00126568 ·Status: TERMINATED ·Phase: PHASE2
-
Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
NCT00060242 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma
NCT01736878 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
NCT00654238 ·Status: COMPLETED ·Phase: PHASE2
-
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
NCT00336063 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
NCT00118170 ·Status: COMPLETED ·Phase: PHASE1
-
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
NCT04759911 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
NCT00410761 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
NCT02657369 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
NCT04165772 ·Status: RECRUITING ·Phase: PHASE2
-
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
NCT04675710 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
NCT02143726 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT05668949 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
NCT00734526 ·Status: TERMINATED ·Phase: PHASE1
-
Safety of TKI258 in Advanced/Metastatic Melanoma Subjects
NCT00303251 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
NCT06475989 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
NCT06066138 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
NCT01379534 ·Status: COMPLETED ·Phase: PHASE2
-
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
NCT01811212 ·Status: COMPLETED ·Phase: PHASE2
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
NCT06959511 ·Status: RECRUITING ·Phase: PHASE2
-
Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function
NCT00275093 ·Status: COMPLETED ·Phase: PHASE1
-
Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
NCT02152995 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
NCT00118248 ·Status: COMPLETED ·Phase: PHASE2